when was semaglutide fda approved U.S. | The FDA has a new higher dose (7.2 mg) of Wegovy ( semaglutide) injection, Wegovy HD, for weight loss and long-term weight Following FDA nod, Novo Nordisk

Mounjaro (Tirzepatide) Dual action: targets both GLP-1 and GIP receptors Strong appetite suppression & improved blood sugar control Clinical trials show average body weight loss up to 22.5% over 72 weeks Wegovy (Semaglutide) Targets GLP-1 receptors only Licensed in the UK for obesity and cardiovascular protection STEP trials show 1521% body weight loss A new 7.2mg dose is expected in late 2025, with results potentially matching Mounjaro Both treatments are once-weekly injections, prescribed alongside healthy diet and lifestyle changes

Control et al., 1993

While these symptoms can be uncomfortable, most tend to improve over time as your body adjusts

PubMed Jastreboff, A.M., Kaplan, L.M., Fras, J.P., Wu, Q., Du, Y., Gurbuz, S., et al